Hideto Morimoto
Kobe, 6590021, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Translational applicability of human blood-brain barrier spheroid models for the development of brain-penetrant therapeutic antibodies.
Journal: Fluids and barriers of the CNS
Published: August 26, 2025
Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.
Journal: Molecular pharmaceutics
Published: October 20, 2023
Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice.
Journal: Molecular therapy. Methods & clinical development
Published: February 16, 2023
Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses.
Journal: International journal of molecular sciences
Published: September 07, 2022
Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice.
Journal: Molecular therapy. Methods & clinical development
Published: February 17, 2022
Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data.
Journal: International journal of molecular sciences
Published: August 25, 2021
Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 16, 2020
Autophagy in the Central Nervous System and Effects of Chloroquine in Mucopolysaccharidosis Type II Mice.
Journal: International journal of molecular sciences
Published: October 15, 2019
Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease.
Journal: Molecular genetics and metabolism
Published: July 17, 2018
Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Journal: Molecular genetics and metabolism
Published: March 07, 2018
A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 14, 2017
Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
Journal: Molecular genetics and metabolism
Published: March 08, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026